Abstract:Objective: This study explored the value of circulating tumor cells (CTC) detected by chromosome 8 centromere probe in diagnosis of non-small cell lung cancer (NSCLC) as well as correlation between CTC counts and clinical pathological characteristics. Methods: We collected 136 patients with newly diagnosed NSCLC (101 males and 35 females, age ranged from 34 to 79 years), 149 patients with non-malignant pulmonary diseases (103 males and 46 females, age ranged from 24 to 80 years) and 32 healthy volunteers (5 males and 27 females, age ranged from 24 to 42 years). Detection was performed using an epithelial cell adhesion molecule-independent strategy that combined immunocytochemistry staining (ICC) of CD(45) and fluorescence in situ hybridization detection (FISH) with chromosome 8 centromere probe (CEP8). CTC was defined as 4',6-diamidino-2-phenylindole (DAPI) positive, CD(45) negative and CEP8 more than 2 positive points. Quantitative data were reported as x±s and Mann Whitney test was used to compare them. Measurement data were analyzed as contingency tables and Pearson chi-squared test was used. P values of less than 0.05 were considered statistically significant. Results: CTCs were detected in 114 patients (83.8%) with NSCLC, 35 patients (23.5%) with non-malignant pulmonary diseases (P<0.000 1) and 5 volunteers (15.6%). CTC counts in NSCLC patients were (5.98±0.64) per 3.2 ml and (0.60±0.13) per 3.2 ml (P<0.000 1). A receiver operating characteristic curve (ROC) analysis showed similar capability of CTC count, with CEA, in discriminating NSCLC and non-malignant diseases with an area under ROC curve of 0.854 (95% confidence interval: 0.808-0.900, P<0.001). Cutoff of 2 circulating tumor cells per 3.2 ml peripheral blood gave the highest Youden Index of 0.614 in diagnosis of NSCLC with sensitivity of 72.1% (98/136) and specificity of 89.3% (133/149). When patients with CTC≥2/3.2 ml peripheral blood or serum CEA≥5 ng/ml were considered as having NSCLC, sensitivity and specificity of this combined test were 87.5% (119/136) and 85.9% (128/149), with a higher Youden Index of 0.734. No correlation was observed between positive rate of CTC (rate of patients with CTC≥2/3.2 ml peripheral blood) and age, gender, smoking status, pathologic types, and clinical stages. Conclusions: CTC counts detected by CD(45)-FISH is higher in NSCLC patients than in non-malignant disease patients. CTC≥2/3.2 ml peripheral blood is valuable in discriminating NSCLC from nonmalignant diseases, which can be more accurate when combined with CEA.

Value of Peripheral Blood MUC1 Mrna and Cyfra21-ⅰ in Diagnosis of Non-Small Cell Lung Carcinoma

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

[Diagnosis Value of the Detection of CYFRA21-1 in Non-Small Cell Lung Cancer].

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Clinical Significance of MUC1 Mrna Expression in Peripheral Blood and Bone Marrow in Patients with Lung Cancer

Detection of Mrna Expression of CK-19 and MUC1 Gene for Diagnosis of Lymph Node Micrometastasis in NSCLC Patients by Reverse Transcriptase-Polymerase Chain Reaction

Application of MSCT Combined with Serum CA125 and CYFRA21-1 in the Diagnosis of Non-small Cell Lung Cancer

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and Its Role in Evaluation of Prognosis

Expression of Profile of MUC1 mRNA in Lymph Node from Patients with Non-small Cell Lung Carcinoma Detected and Its Clinical Significance

Clinical Value of Serum CYFRA 21-1, NSE and CEA in the Diagnosis and Prognosis of Lung Cancer

Diagnostic Value of Cytokeratin-19 Fragments, Neuron Specific Enolase and Pro-Gastrin Releasing Peptide in Serum for Primary Lung Cancer

[Correlation of the Expression of III Β-Tubulin and MDR1 Protein with Biological Features of Non-Small Cell Lung Cancer].

Application Value of CYFRA21-1 Combined with NSE, CEA, and SCC-Ag in Lung Cancer.

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

Clinical Significance of Cytokeratin 19 Mrna in the Peripheral Blood of Non-Small Cell Lung Cancer

Molecuar Detection of MUC1-positive Cells in Peripheral Blood of Patients with Non-Small-cell Lung Cancer

Expression and Prognostic Relevance of MUC1 in Stage IB Non-Small Cell Lung Cancer

Diagnostic value of human circulating tumor cell detection for non-small cell lung cancer

ROC curve in the evaluation of diagnostic value of the detection of CEA and CYFRA21-1 for non-small cell lung cancer

Determination of CA153,CA242 and CYFRA21-1 in Serum of Patients with Non-Small Cell Lung Cancer

CYFRA21-1 Tests in the Diagnosis of Non-Small Cell Lung Cancer: A Meta-Analysis.